<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954652</url>
  </required_header>
  <id_info>
    <org_study_id>WG-Trio01</org_study_id>
    <nct_id>NCT03954652</nct_id>
  </id_info>
  <brief_title>Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - &quot;GENOME FIRST APPROACH&quot;</brief_title>
  <official_title>Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - &quot;GENOME FIRST APPROACH&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GENOME FIRST APPROACH project will enroll patients (n = 450) and their healthy parents&#xD;
      with unclear molecular cause of the disease, suspected genetic cause of the disease and the&#xD;
      healthy parents of those affected for trio analysis (N in total 1350).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the GENOME FIRST APPROACH (monocentric, prospective, open-label diagnostic) project,&#xD;
      patients with molecularly undiagnosed diseases will diagnostically be analyzed by Whole&#xD;
      Genome Sequencing (WGS)-trio analysis. The following questions will be leading the project:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      • Efficacy of WGS trio analysis in different clinical indications&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  Systematically benchmark WGS analysis to detect genetic variations compared to WES and&#xD;
           single nucleotide polymorphism (SNP) array analysis,&#xD;
&#xD;
        -  Expand the analysis from coding single-nucleotide variants (SNVs) to regulatory&#xD;
           mutations, structural variants (SVs), and low complexity regions,&#xD;
&#xD;
        -  Validate the efficacy of clinical genome trio sequencing in a routine diagnostic&#xD;
           setting,&#xD;
&#xD;
        -  Analyse whether 42x coverage has the potential to discover mosaicism as disease causing&#xD;
           mechanism,&#xD;
&#xD;
        -  Further develop algorithms for integrative analyses of Trio-WGS data with Ribonucleic&#xD;
           acid- sequencing (RNA-seq),&#xD;
&#xD;
        -  Identify de novo alterations and novel disease mechanisms,&#xD;
&#xD;
        -  Gain fundamental new insights into disease mechanisms and cellular biology,&#xD;
&#xD;
        -  Combine WGS with further Omics methods to improve genetic diagnostics of future rare&#xD;
           disease patients, and&#xD;
&#xD;
        -  Explore overall financial costs and time to report conclusive data to the patients of&#xD;
           the Trio-WGS approach compared to traditional multistep diagnostic approaches using&#xD;
           single-gene, panel, whole-exome sequencing (WES) and chromosomal microarray (CMA) (SNP&#xD;
           array, array-based comparative genomic hybridization (arrayCGH)) analysis.&#xD;
&#xD;
      In addition, healthy parents of the subjects will be included in the project to perform&#xD;
      parent-child (trio) analyzes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cohort 1: IQ &lt; 70 with and without malformations, syndromic and non-syndromic Cohort 2: Retinitis pigmentosa, achromatopsy, Bardet-Biedl syndrome, Usher syndrome, congenital stationary night blindness, LCA, macula degeneration, rod/ cone dystrophies, opticus atrophy Cohort 3: Rare paediatric solid cancers as melanoma, carcinoma of the gastrointestinal tract, tumours of the salivary gland and pancreatic tumors in children.&#xD;
Plus: their respective parents</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Full genomic sequence analysis carried out by Whole Genome Sequencing (WGS)</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of genomic variants in disease and health parents by WGS (a Next-Generation Sequencing Technology, NGS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genome sequencing</measure>
    <time_frame>Day 1</time_frame>
    <description>Verification of the genetic causes of unclear genetic diseases by clinical genome sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>De novo alterations</measure>
    <time_frame>Day 1</time_frame>
    <description>Number of de novo alterations in genome of the enrolled population</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1350</enrollment>
  <condition>Rare Diseases</condition>
  <condition>Genetic Predisposition</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Intellectual disability</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Genetic: WGS Diagnostic Blood take for genetic diagnostic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Retinal diseases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Genetic: WGS Diagnostic Blood take for genetic diagnostic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Rare tumors in childhood</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Genetic: WGS Diagnostic Blood take for genetic diagnostic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>WGS-Diagnostic</intervention_name>
    <description>Blood sampling, shot clinical characterization, WGS-based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA-seq.</description>
    <arm_group_label>Cohort 1: Intellectual disability</arm_group_label>
    <arm_group_label>Cohort 2 Retinal diseases</arm_group_label>
    <arm_group_label>Cohort 3: Rare tumors in childhood</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unclear molecular cause of the disease&#xD;
&#xD;
          -  Suspected genetic cause of the disease&#xD;
&#xD;
          -  Healthy parents of those affected for trio analysis Cohort 1: IQ &lt; 70 with and without&#xD;
             malformations, syndromic and non-syndromic Cohort 2: Retinitis pigmentosa,&#xD;
             achromatopsy, Bardet-Biedl syndrome, Usher syndrome, congenital stationary night&#xD;
             blindness, LCA, macula degeneration, rod/ cone dystrophies, opticus atrophy Cohort 3:&#xD;
             Rare paediatric solid cancers as melanoma, carcinoma of the gastrointestinal tract,&#xD;
             tumours of the salivary gland and pancreatic tumors in children.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cohort 1: Toxic causes (drugs, infections) Cohort 2: patients with non-genetic forms of&#xD;
        blindness Cohort 3: adult cancer, blood cancer&#xD;
&#xD;
          -  Missing informed consent of the patient/ legal guardian&#xD;
&#xD;
          -  Missing samples of both parents&#xD;
&#xD;
          -  Previous WES or panel analysis-&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olaf Riess, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Tübingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olaf Riess, Prof. Dr.</last_name>
    <phone>+49 7071 298</phone>
    <phone_ext>72323</phone_ext>
    <email>olaf.riess@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tobias Haack, Dr.</last_name>
    <phone>+49 7071 298</phone>
    <phone_ext>77696</phone_ext>
    <email>tobias.haack@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olaf Rieß, Prof. Dr.</last_name>
      <phone>+49 7071-297</phone>
      <phone_ext>2323</phone_ext>
      <email>olaf.riess@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Tobias Haack, Dr.</last_name>
      <phone>+49 7071-297</phone>
      <email>tobias.haack@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rare Diseases</keyword>
  <keyword>Genetic Predisposition</keyword>
  <keyword>Whole-exome sequencing</keyword>
  <keyword>WGS-trio analysis</keyword>
  <keyword>Whole Genome Sequencing (WGS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rare Diseases</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

